Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UVEAL MELANOMA IN A 15-YEAR-OLD GIRL. CASE REPORT.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2021
Same author

BILATERAL OPTIC DISC PIT WITH MACULOPATHY - THE CASE REPORT.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2019
Same author

Primary orbital teratoma - case study.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2019
Same author

Idiopathic Chodoidal Neovascular Membrane in a 12-year-old Girl.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2019
Same author

Molecular Classification of Medullobastomas by Whole Genome Expression Profiling.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2019
Same author

Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2019

Related Experiment Video

Updated: Dec 21, 2025

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

327

NEUROFIBROMATOSIS TYPE 1 AND OPTIC PATHWAY GLIOMA.

A Siwá, R Autrata, K Vejmělková

    Ceska a Slovenska Oftalmologie : Casopis Ceske Oftalmologicke Spolecnosti a Slovenske Oftalmologicke Spolecnosti
    |May 14, 2020
    PubMed
    Summary

    Chemotherapy is the preferred treatment for optic pathway glioma, often stabilizing vision. However, treatment effectiveness for pediatric patients requires further study due to variable examination intervals and challenges in assessing visual function.

    Keywords:
    chemotherapychildrenneurofibromatosisoptic pathway gliomatreatment

    More Related Videos

    Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
    05:44

    Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

    Published on: May 17, 2024

    916
    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.4K

    Related Experiment Videos

    Last Updated: Dec 21, 2025

    An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
    03:53

    An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

    Published on: October 10, 2025

    327
    Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
    05:44

    Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

    Published on: May 17, 2024

    916
    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.4K

    Area of Science:

    • Ophthalmology
    • Pediatric Oncology
    • Neuro-oncology

    Background:

    • Optic pathway glioma (OPG) is a significant cause of vision loss in children, particularly those with neurofibromatosis.
    • Evaluating treatment effectiveness for OPG is complex due to varied patient presentations and assessment challenges.

    Purpose of the Study:

    • To assess the effectiveness of current treatments for pediatric patients diagnosed with optic pathway glioma.
    • To compare clinical outcomes with existing literature on OPG and neurofibromatosis.

    Main Methods:

    • Retrospective analysis of pediatric patients with OPG treated between January 2013 and June 2018.
    • Literature review of neurofibromatosis and optic pathway glioma research.

    Main Results:

    • Chemotherapy is the primary treatment modality, with a high likelihood of stabilizing visual acuity.
    • Tumor progression does not consistently correlate with decreased visual acuity.
    • Age at treatment initiation and tumor location are key risk factors influencing outcomes.

    Conclusions:

    • The study cohort outcomes align with existing literature, supporting chemotherapy as the standard of care.
    • Further research is needed to identify predictive biomarkers for visual acuity loss.
    • Improved collaboration and standardized ophthalmologic examinations are crucial for accurate treatment evaluation.